Stock Watch: Why Have Biotech Acquisitions Paused?
Pharma’s Appetite For Biotech Acquisitions Has Declined In 2021
The subdued number of acquisitions of biotech by big pharma has more than one cause. The structural improvement of the process of drug discovery and development at big pharma is the main one.
You may also be interested in...
The German biotech had already hinted at possibly expanding through M&A, and Constellation was viewed as an attractive acquisition target.
Are three FDA clinical holds in less than four days a symptom of lax safety programs at some biotech companies? And what does the latest publication on Aduhelm say about the relationship between safety and accelerated approval?
While the stock prices of a few biotech companies have advanced significantly as a result of their pandemic efforts, a broad biotech stock index has underperformed the pharmaceutical index. Why?